Home workouts may boost muscle power in kidney patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate-severe CKD determined by estimated glomerular filtration rate (eGFR) \<60ml/min per 1.73m2 * No history chronic treatment with dialysis. * Age 30 years old to 75 years * Sedentary defined as self-reporting no more than 1 day per week of regular (structured) endurance exercise (EE) \[e.g., brisk walking, jogging/running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate or rapid breathing (EE), and/or sweating\] or resistance exercise (RE) (resulting in muscular fatigue) lasting no more than 60 minutes in the past year. * Persons bicycling as a mode of transportation to/from work \> 1 day/week etc. are not considered sedentary * Leisure walkers are included unless they meet the heart rate, breathing and sweating criteria noted above * Persons adherent to both 1 day/week of RE and 1 day/week of EE are excluded Exclusion Criteria: * Current or previous transplantation * Current pregnancy (all females of child-bearing potential will have a pregnancy test) * Wheelchair dependence or other disability that precludes physical exercise * Oxygen dependent Chronic obstructive pulmonary disease (COPD) * Shortness of breath after walking \<100 steps on flat surface * Weight \>300 pounds * HIV infection or hepatitis viral infection * Decompensated cirrhosis * Active malignant cancer other than non-melanomatous skin cancer * Drugs that alter mitochondrial function: * muscle relaxants (methocarbamol, baclofen, tizanidine, carisoprodol, cyclobenzaprine) * oral steroids (Equivalent of 10mg or more of prednisone daily) * anti-viral medications (tenofovir, zalcitabine, didanosine, stavudine, lamivudine, zidovudine, abacavir, adefovir, interferon, ribavirin, efavirenz, dasabuvir, ombitasvir) * oral calcineurin inhibitors (Tacrolimus, Cyclosporine) * Antiepileptic drugs (Phenytoin, phenobarbital, carbamazepine, valproic acid, oxcarbazepine, ethosuximide, zonisamide, topiramate, and vigabatrin) * Antipsychotics (haloperidol, thioridazine, risperidone, quetiapine, clozapine, olanzapine and aripiprazole) * Drugs- anticoagulants or antiplatelets * Anticoagulants, any 1 (coumadin, rivaroxaban, apixaban, dabigatran, edoxaban) * Antiplatelets, any 2 (aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticagrelor, ticlopidine, vorapaxar) * Implants that prohibit MRI measurements or trauma involving metal fragments * Pacemaker * History of clotting disorder (Deep venous thrombosis, pulmonary embolism) or bleeding disorder. * History of sever heart disease/disorders: coronary artery bypass graft (CABG) surgery, atrial fibrillation * Vascular stent: bare metal or any recently placed (within 6 months) * Current substance abuse * Institutionalization * Current participation in an interventional trial * Inability to provide informed consent without a proxy respondent * Non-English speaking * Any condition which in the judgement of the clinical investigator places the participant at risk from participation in the study. Additional Criteria: * On chronic dialysis * Expectation to start dialysis within 6 months. * High dose antioxidants (Vitamine C, Vitamin E) * Baseline systolic blood pressure \>170 or diastolic blood pressure \>100 * Uncontrolled diabetes with a HgbA1c \>8.5 * Active uncontrolled thyroid disease * Anemia (Hgb \<9 g/dL) * Current substance abuse (i.e. amphetamine abuse) * Chronic opioid use (i.e. for chronic pain) * Chronic use of immunosuppressants * Active coronary ischemia detected by ECG on cycle ergometry VO2max testing. These individuals will be promptly referred to their primary care provider by the PI.